Is There an Ozempic Pill? How It Compares to Rybelsus and the Wegovy Pill

Is Rybelsus the same as Ozempic?

No, but they're close: Rybelsus and the Ozempic tablet are two brand names on one shared FDA label, at different strengths, and all three products — plus Wegovy — contain semaglutide from the same manufacturer. CMS lists "Ozempic; Rybelsus; Wegovy (Novo Nordisk Inc.)" as a single selected drug in its Medicare price negotiation. One molecule, three brand names, two routes — for how the Ozempic and Wegovy brands differ overall, see what is the difference between Ozempic and Wegovy.

Wegovy adds a layer. Wegovy is marketed in two distinct dosage forms under a single brand name and a single FDA label: WEGOVY (semaglutide) injection, solution, and WEGOVY (semaglutide) tablet. Prescribers must specify which form is intended, as dosing schedules and indications differ between them.

And the tablets are not interchangeable by milligram. OZEMPIC tablet strengths (1.5 mg, 4 mg, 9 mg) are different from the RYBELSUS tablet strengths (3 mg, 7 mg, 14 mg) on the same shared label, so the two brands are not interchangeable milligram-for-milligram.

Ozempic, Rybelsus, and Wegovy at a glance

How does the Ozempic tablet dose compare to Rybelsus?

Both ramp over the same two-month schedule but at different milligram numbers, so a pharmacy cannot substitute one for the other by dose alone. The Ozempic tablet ramps over two months. OZEMPIC tablets are started at 1.5 mg orally once daily for days 1 through 30. The 1.5 mg starting dosage of OZEMPIC tablets is an initiation dosage and is not effective for glycemic control. On days 31 to 60, the OZEMPIC tablet dosage is increased to 4 mg orally once daily. On day 61 or thereafter, the OZEMPIC tablet dosage is maintained at 4 mg once daily if no additional glycemic control is needed, or increased to 9 mg once daily if additional glycemic control is needed. The maximum recommended dosage of OZEMPIC tablets is 9 mg once daily.

The tablet also has a heart indication. OZEMPIC tablets are indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.

What is the Wegovy pill, and how well does it work?

The Wegovy pill is oral semaglutide labeled for weight reduction, reaching a 25 mg once-daily maintenance dose by day 91; in its OASIS 4 trial it produced a -13.6% average body-weight change at week 64. Wegovy tablets are available in strengths of 1.5 mg, 4 mg, 9 mg, and 25 mg. Wegovy tablets are escalated on a 30-day-per-step schedule: 1.5 mg once daily on days 1-30, 4 mg once daily on days 31-60, 9 mg once daily on days 61-90, then 25 mg once daily as the maintenance dose from day 91 onward.

Per the OASIS 4 trial publication as sourced in August 2026: in the OASIS 4 trial, mean change in body weight at week 64 was -13.6% with oral semaglutide 25 mg once daily versus -2.2% with placebo (estimated difference -11.4 percentage points), in a 71-week trial of 307 adults (205 semaglutide, 102 placebo). OASIS 4 enrolled adults without diabetes who had a body-mass index of 30 or higher, or a BMI of 27 or higher with at least one obesity-related complication.

For context on the injection, as sourced in August 2026: in the STEP 1 trial, mean change in body weight from baseline to week 68 was -14.9% with once-weekly subcutaneous semaglutide 2.4 mg versus -2.4% with placebo, in 1,961 adults with overweight or obesity without diabetes. These are separate trials with different durations and sizes, not a head-to-head comparison.

Who the pill is for differs from the pen. The indications for Wegovy tablets are limited to adults; the pediatric weight-reduction indication for patients aged 12 years and older applies to Wegovy injection only. Both Wegovy injection and Wegovy tablets are indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. Wegovy injection is indicated for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (stages F2 to F3) in adults, under accelerated approval; this indication does not apply to Wegovy tablets.

How do you take an oral semaglutide tablet?

Every oral semaglutide product has the same morning routine. Wegovy tablets are taken orally once daily on an empty stomach in the morning with up to 4 ounces of water; the patient must wait at least 30 minutes before eating food, drinking other beverages, or taking other oral medications. Wegovy tablets must be swallowed whole and must not be split, crushed, chewed, or dissolved. The diabetes tablet is the same: OZEMPIC tablets are taken on an empty stomach when first waking, with no more than 4 ounces of plain water.

The injection is less fussy about timing. Wegovy injection is administered subcutaneously in the abdomen, thigh, or upper arm, once weekly on the same day each week, with or without meals.

Do not stack products. Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.

How much does the Wegovy pill cost, and will insurance cover it?

Self-pay starts at $149/mo for the Wegovy pill's 1.5 mg dose and rises to $299/mo at the 25 mg maintenance dose; whether insurance covers it at all depends entirely on your plan's formulary. The three products carry different labeled indications and formulations — Ozempic tablet and Rybelsus share one FDA label, while Wegovy has its own — and a plan's formulary decision tracks that indication, not the molecule. A formulary is the list of prescription drugs covered by a prescription drug plan or other insurance plan offering prescription drug benefits; plans commonly layer prior authorization, step therapy, or quantity limits on top of a formulary listing. Whether any given plan covers the Ozempic tablet, Rybelsus, or the Wegovy pill — and under what conditions — depends on that plan's specific rules. Measured states that many insurance plans require a prior authorization before they will cover brand-name GLP-1s such as Ozempic, Wegovy, Mounjaro, or Zepbound. Preauthorization is not a promise that the health insurance plan will cover the cost of the service or drug.

List prices first. The CY 2024 list price for a 30-day supply of the selected drug Ozempic; Rybelsus; Wegovy was $959. As of August 2026, Novo Nordisk states a list price of $1,349.02 per package for the Wegovy pill, the Wegovy pen, and the Wegovy HD pen; list price is the manufacturer price before discounts or rebates, and most insured patients pay less.

Self-pay offers are lower. As of August 24, 2026, per Novo Nordisk's price guide: the Wegovy pill is $149/mo for the 1.5 mg dose; the 4 mg dose is also $149/mo as a limited-time offer through August 31, 2026, after which it moves to $199/mo; the 9 mg and 25 mg doses (25 mg is the maintenance dose) are $299/mo. For the pen: $199/mo for new patients' first 2 months at the 0.25 mg or 0.5 mg doses (offer through December 31, 2026), then $349/mo; 1 mg, 1.7 mg, and 2.4 mg are $349/mo; the Wegovy HD 7.2 mg pen is $399/mo. These are promotional prices set by the manufacturer and can change without notice.

Medicare has its own track. CMS negotiated a Medicare maximum fair price of $274 for a 30-day supply of the selected drug Ozempic; Rybelsus; Wegovy (Novo Nordisk Inc.), taking effect January 1, 2027. The negotiated Medicare price for Ozempic; Rybelsus; Wegovy represents a 71% discount from the 2024 list price. Separately, Novo Nordisk states that all dose strengths of the Wegovy pen and pill are available for $50 per month under the Medicare GLP-1 Bridge program, running July 1, 2026 through December 31, 2027 — but only for beneficiaries who meet the program's own eligibility rules, not every Part D enrollee. See does Medicare cover Zepbound and what is the Medicare GLP-1 Bridge for the full eligibility breakdown.

What are the side effects and safety warnings?

The tablets and injections share the same warnings. Wegovy carries a boxed warning for risk of thyroid C-cell tumors: in rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). OZEMPIC tablets are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Stomach effects are the common complaint, but the exact list is not the same across products. Per the Wegovy label, the most common adverse reactions (incidence at or above 5%) in adults or pediatric patients aged 12 years and older are nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss. Per the shared Ozempic tablet/Rybelsus label, the most common adverse reactions (incidence at or above 5%) are nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation — a shorter list, from an older adult population studied for glycemic control rather than weight loss. For the Wegovy pill specifically, per the trial as sourced in August 2026: in OASIS 4, gastrointestinal adverse events were more common with oral semaglutide 25 mg than with placebo (74.0% versus 42.2%).

How Measured fits in

Measured prescribes FDA-approved GLP-1 medications and compounded alternatives, specifically semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), compounded alternatives when brand medications are unavailable, and oral medications including metformin, topiramate, and bupropion/naltrexone. For patients with commercial insurance, Measured performs a benefits check to determine which medications may be covered under the patient's plan. Measured's insurance concierge team submits prior authorizations on the patient's behalf and keeps the patient updated on the insurance plan's determination.

Nothing here guarantees coverage, approval, or a result. A licensed provider reviews your history and decides which product, if any, is appropriate.